Literature DB >> 22375522

Nonalcoholic fatty liver disease and bariatric surgery.

Sindu Stephen1, Ancha Baranova, Zobair M Younossi.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. Treatment recommendations for NAFLD are aimed towards weight reduction, thereby reducing insulin resistance. Unfortunately, lifestyle modifications have not yielded long-term success, while durable weight loss is routinely achieved with bariatric surgery. This article reviews the effects of bariatric surgery on patients with NAFLD. In these patients, postsurgical evaluations of liver histology by repeat liver biopsy are hindered by the risk of the procedure and the inherent sample variability, which makes the impact of bariatric surgery on NAFLD difficult to quantify. In longitudinal studies of NAFLD, the biopsy-based evaluations should be augmented by repeated measurements of the noninvasive biomarkers that may provide an insight into the changes in the physiological state of the liver after bariatric or other types of interventions. Nevertheless, currently available tests are not able to provide this type of in-depth outcome measures for these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22375522     DOI: 10.1586/egh.11.97

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  7 in total

Review 1.  Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

Authors:  Juan P Arab; Roberto Candia; Rodrigo Zapata; Cristián Muñoz; Juan P Arancibia; Jaime Poniachik; Alejandro Soza; Francisco Fuster; Javier Brahm; Edgar Sanhueza; Jorge Contreras; M Carolina Cuellar; Marco Arrese; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.

Authors:  Amanda Karolina Soares Silva; Christina Alves Peixoto
Journal:  Cell Mol Life Sci       Date:  2018-05-22       Impact factor: 9.261

Review 3.  Non-alcoholic fatty liver disease in 2015.

Authors:  Monjur Ahmed
Journal:  World J Hepatol       Date:  2015-06-18

4.  Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease.

Authors:  Martin L Decaris; Claire L Emson; Kelvin Li; Michelle Gatmaitan; Flora Luo; Jerome Cattin; Corelle Nakamura; William E Holmes; Thomas E Angel; Marion G Peters; Scott M Turner; Marc K Hellerstein
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

Review 5.  Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.

Authors:  Sukhpreet Singh; Natalia A Osna; Kusum K Kharbanda
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

6.  Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.

Authors:  Sandra Page; Aybike Birerdinc; Michael Estep; Maria Stepanova; Arian Afendy; Emanuel Petricoin; Zobair Younossi; Vikas Chandhoke; Ancha Baranova
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

7.  HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels.

Authors:  Changxi Chen; Zhongwei Zhu; Yushan Mao; Yimin Xu; Juan Du; Xiaoping Tang; Hongbao Cao
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.